Powder: -20°C for 3 years | In solvent: -80°C for 1 year
YL-109, a novel anticancer agent, can inhibit breast Y cell growth and invasiveness in vitro and in vivo.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 33.00 | |
5 mg | In stock | $ 52.00 | |
10 mg | In stock | $ 79.00 | |
25 mg | In stock | $ 145.00 | |
50 mg | In stock | $ 213.00 | |
100 mg | In stock | $ 320.00 | |
200 mg | In stock | $ 482.00 | |
500 mg | In stock | $ 789.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 54.00 |
Description | YL-109, a novel anticancer agent, can inhibit breast Y cell growth and invasiveness in vitro and in vivo. |
Targets&IC50 | MCF-7 cells proliferation:85.7 nM |
Molecular Weight | 257.31 |
Formula | C14H11NO2S |
CAS No. | 36341-25-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (213.75 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
YL-109 36341-25-0 Immunology/Inflammation Metabolism Aryl Hydrocarbon Receptor AhR inhibit aryl hydrocarbon,AhR antitumor carboxyl breast Hsp70-interacting CHIP YL 109 protein cancer terminus YL109 invasiveness Inhibitor inhibitor